Episode 04/
The role of wastewater surveillance in the next phase of the COVID-19 pandemic

15 May, 2021

With many public health experts believing that COVID-19 will continue to be a global health problem for years to come, the need for SARS-CoV-2 testing will remain. However, the type of testing will likely change. For regions where the virus is not very widespread and the number of diagnostic tests has declined, surveillance testing of wastewater for SARS-CoV-2 can be an efficient and cost-effective way to understand and anticipate potential outbreaks.
In this episode, we speak with three scientists from Combinati, a company that has commercialised a digital PCR platform, on how their technology is being used by universities and municipalities in the United States to analyse wastewater for SARS-CoV-2 surveillance, and the unique advantages of digital PCR for this application.

Podcast Episode Image

Our Guests

Robert Lin
Robert Lin, PhD, is the Director of R&D at Combinati. Robert brings over ten years of microfluidics research and diagnostics platform development to the team. In addition to authoring publications ranging from droplet microfluidics to proteomic assays, Robert managed teams for platform R&D as well as high volume injection molded consumables in the industrial environment.

Christina Bouwens
Christina Bouwens is a Senior Application Scientist at Combinati. She has a background in digital PCR assay development and next generation sequencing technologies with specific focus on applications to cancer biology and precision medicine. She was the recipient of the 2018 AMP Technologist Award, and has contributed to 11 peer-reviewed publications in the Oncology space - including two first authorship's utilising digital PCR technology for personalised circulating tumor DNA detection and monitoring.

Adam Langston
Adam Langston is the VP of Sales & Business Development at Combinati. He has a decade of experience in emerging and established life science equipment, reagent, and service commercialisation. Prior to joining Combinati, he consulted biologists across academic and industrial labs for companies large and small-- including MilliporeSigma, CellASIC and Bio-Techne. After years as an environmental laboratory scientist, he understands how and why researchers evaluate and adopt new technologies. Adam considers himself a customer advocate above all else, and is excited to share and support Combinati’s innovative solutions with investigators all over the world.
Meet our host
Pia Abola, PhD
Pia Abola, PhD, has spent the past ten years providing content marketing for life science companies. Before becoming a marketer she used protein biochemistry and molecular biology to study site-specific recombination, plant-bacteria symbiosis, and signal transduction. She also worked on the human genome sequencing project and and at an anti-viral drug discovery company.

Enabling your rapid response to the pandemic

COVID Resource Hub